Amundi Asset Management US’s Integra LifeSciences IART Stock Holding History

Amundi Asset Management US’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-46,800	Closed	-$2.81M	–	1631
2019 Q3	$2.81M	Buy	46,800 +40,900	+693%	+$2.44M	﹤0.01%	1023
2019 Q2	$330K	Hold	5,900	–	–	﹤0.01%	1409
2019 Q1	$329K	Buy	+5,900	New	+$300K	﹤0.01%	1366
2018 Q4	–	Sell	-16,900	Closed	-$1.11M	–	1628
2018 Q3	$1.11M	Buy	+16,900	New	+$1.05M	﹤0.01%	1244

Other funds holding IART

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Amundi Asset Management US's IART Position: Q4 2019 in Review

Amundi Asset Management US sold out of Integra LifeSciences (IART) in Q4 2019, closing a stake of 46,800 shares — an estimated $2.81M sold.

Amundi Asset Management US first reported a position in IART in Q3 2018 and held it in 4 quarters. The position peaked at $2.81M in Q3 2019. 279 funds tracked by Wall St. Rank hold IART as of Q4 2019.

Amundi Asset Management US reported no remaining Integra LifeSciences position as of Q4 2019 after selling out during the quarter.
Amundi Asset Management US sold 46,800 Integra LifeSciences shares in Q4 2019, an estimated $2.81M.
Amundi Asset Management US first reported a position in Integra LifeSciences in Q3 2018 and held it in 4 quarters.
Amundi Asset Management US's Integra LifeSciences position peaked at $2.81M in Q3 2019.
279 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2019.

Based on Amundi Asset Management US's 13F filing for Q4 2019, filed 14 Feb 2020.